Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380019 | 0.83 | — | — | |
| Phosphonic Acid SCHEMBL3380653 | 0.80 | CA12 (0.38) | CA12CA1CA2CA9 | |
| Phosphonic Acid SCHEMBL1191783 | 0.71 | — | — | |
| Phosphonic Acid SCHEMBL1191902 | 0.71 | — | — | |
| Phosphonic Acid SCHEMBL9705797 | 0.67 | RNPEP (0.39) | MAPK1 | |
| Phosphonic Acid SCHEMBL7866708 | 0.67 | RNPEP (0.39) | MAPK1 | |
| Phosphonic Acid SCHEMBL1199957 | 0.67 | — | — | |
| Phosphonic Acid SCHEMBL1199764 | 0.67 | TSHR (0.39) | CA1 | |
| Phosphonic Acid SCHEMBL3379299 | 0.67 | — | — | |
| Isobutane SCHEMBL5096181 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | claimed |
| US-20120282351-A1 | System and Method for The Prevention of Bacterial and Fungal Infections Including Urinary Tract Infections (UTI) Using N-Halogenated Amino Acids | NOVABAY PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | claimed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | claimed |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | claimed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | claimed |
| US-20100010456-A1 | System and Method for the Prevention of Bacterial and Fungal Infections Including Urinary Tract Infection (UTI) Using N-Halogenated Amino Acids | NOVACAL PHARMACEUTICALS, INC. | 2010-01-14 | — | — | US | claimed |
| US-20070244449-A1 | System and method for the prevention of bacterial and fungal infections including Urinary Tract Infections (UTI) using N-halogenated amino acids | NOVACAL PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | claimed |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | NOVABAY PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | claimed |
| EP-2265267-B1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | GOTTARDI WALDEMAR (AT) | 2016-09-21 | — | — | EP | disclosed |
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | disclosed |
| EP-2725008-A1 | N,N-dihalogenated amino acids and derivatives | NovaBay Pharmaceuticals, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20120282351-A1 | System and Method for The Prevention of Bacterial and Fungal Infections Including Urinary Tract Infections (UTI) Using N-Halogenated Amino Acids | NOVABAY PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| US-7893109-B2 | N,N-dihalogenated amino acids and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100010456-A1 | System and Method for the Prevention of Bacterial and Fungal Infections Including Urinary Tract Infection (UTI) Using N-Halogenated Amino Acids | NOVACAL PHARMACEUTICALS, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20090023812-A1 | N,N-DIHALOGENATED AMINO ACIDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-7462361-B2 | N,N-dihalogenated amino acids and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070244449-A1 | System and method for the prevention of bacterial and fungal infections including Urinary Tract Infections (UTI) using N-halogenated amino acids | NOVACAL PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | NOVABAY PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | disclosed |
| US-20050065115-A1 | N,N-dihalogenated amino acids and derivatives | NOVABAY PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023812-A1 | N,N-DIHALOGENATED AMINO ACIDS AND DERIVATIVES | DAO, DDC, NRDC | CA12 4770/4885CA1 4651/4885CA2 4487/4885 |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | POLR1C, TYR, NACA | CA12 3048/4885CA1 4102/4885CA2 4297/4885 |
| US-20140227201-A1 | Antimicrobial Gel Formulations | CUTA, TUBA3C, POLR1C | CA12 4659/4885CA1 4807/4885CA2 4749/4885 |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | CFTR, NAT1, ELANE | CA12 3693/4885CA1 4304/4885CA2 4543/4885 |
| US-20050065115-A1 | N,N-dihalogenated amino acids and derivatives | DAO, DDC, NRDC | CA12 4770/4885CA1 4651/4885CA2 4487/4885 |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | CUTA, TUBA3C, POLR1C | CA12 4659/4885CA1 4807/4885CA2 4749/4885 |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | DAO, ASNS, DDC | CA12 4591/4885CA1 3944/4885CA2 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.